GPVI inhibition by glenzocimab synergistically inhibits atherosclerotic plaque-induced platelet activation when combined with conventional dual antiplatelet therapy
Sign Up to like & getrecommendations! Published in 2021 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehab724.1425
Abstract: Aspirin and a potent platelet P2Y12 inhibitor, such as prasugrel or ticagrelor, are not always sufficient to prevent thrombus formation in patients with ST-elevation MI (STEMI), leading to “slow flow” or “no reflow” effects after… read more here.
Keywords: glenzocimab; aspirin ticagrelor; gpvi; atherosclerotic plaque ... See more keywords
Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke.
Sign Up to like & getrecommendations! Published in 2022 at "Stroke"
DOI: 10.1161/strokeaha.122.039790
Abstract: It has previously been shown in several animal experiments that platelet GPVI (glycoprotein VI) contributes to thrombosis, particularly in ischemic stroke. Moreover, GPVI levels are upregulated in stroke patients. This review describes the therapeutic roles… read more here.
Keywords: glenzocimab; gpvi glycoprotein; acute ischemic; stroke ... See more keywords
Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007863
Abstract: Key Points • Crystallization studies map the binding of glenzocimab to the site of dimerization in the D2 domain of GPVI.• Glenzocimab inhibits GPVI interactions with CRP, collagen, and fibrin by loss of dimerization, conformational… read more here.
Keywords: glenzocimab novel; glenzocimab; gpvi glenzocimab; platelet gpvi ... See more keywords